Shopping Cart
Remove All
Your shopping cart is currently empty
Tofimilast
Copy Product Info
🥰Excellent
Catalog No. T28991Cas No. 185954-27-2
Alias CP-325366, CP325366, CP-325,366, CP 325366, CP 325,366
Tofimilast (CP-325366), a PDE4 inhibitor, is used potentially for the treatment of asthma and chronic obstructive pulmonary disease.
Tofimilast
Copy Product Info🥰Excellent
Purity: 99.55%
Catalog No. T28991Alias CP-325366, CP325366, CP-325,366, CP 325366, CP 325,366Cas No. 185954-27-2
Tofimilast (CP-325366), a PDE4 inhibitor, is used potentially for the treatment of asthma and chronic obstructive pulmonary disease.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $88 | In Stock | In Stock | |
| 5 mg | $210 | In Stock | In Stock | |
| 10 mg | $318 | In Stock | In Stock | |
| 25 mg | $515 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.55%
Appearance:Solid
Color:Yellow
Contact us for more batch information
Product Introduction
Tofimilast AI Summary
Tofimilast exhibits bioactivities related to phosphodiesterase inhibition, showing varying IC50 values for different PDE enzymes. It increases cAMP levels in stimulated cells and inhibits TNF alpha release in monocytes. The compound has moderate to high bioavailability in rats and dogs, with plasma concentration measures of 152.0 ng/ml in ferrets and oral bioavailability of 1.2% in rats and 3.0% in dogs. It also displays a low to high plasma protein binding rate, with percentages ranging from 95.23% to 96.26% in rat and human plasma, alongside favorable clearance, volume of distribution, and half-life values across various species. The compound's log D value of 3.5 to 3.6 at pH 7.4 indicates moderate lipophilicity, contributing to its distribution and absorption properties. Additionally, it shows favorable intrinsic clearance in human and rat hepatocytes, with values from 6.0 to 73.0 uL.min-1.(10^6 cells)-1, and has good solubility in pH 7.4 buffer, with a measured solubility of 22,400.0 nM..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Tofimilast (CP-325366), a PDE4 inhibitor, is used potentially for the treatment of asthma and chronic obstructive pulmonary disease. |
| Targets&IC50 | PDE4:0.14 μM |
| Synonyms | CP-325366, CP325366, CP-325,366, CP 325366, CP 325,366 |
| Molecular Weight | 339.46 |
| Formula | C18H21N5S |
| Cas No. | 185954-27-2 |
| Smiles | C(C)C=1C2=C(C=3N(C(=NN3)C4=CC=CS4)CC2)N(N1)C5CCCC5 |
| Relative Density. | 1.48 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (132.56 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Tofimilast | purchase Tofimilast | Tofimilast cost | order Tofimilast | Tofimilast chemical structure | Tofimilast formula | Tofimilast molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.